Radiosurgery and Immunotherapy for Melanoma Patients With Brain Metastases

TLX101 is currently under assessment as a treatment for glioma in the IPAX-2 and IPAX-Linz studies.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

Jonathan Zager, MD, spoke about the use of observation vs systemic immunotherapy to treat patients with stage IIIA and IIIB melanoma.

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.

Findings from a phase 1b trial support the tolerability and potential survival benefit of CAN-3110 as a treatment for patients with recurrent high-grade glioma.